New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
06:32 EDTPCRXPacira Pharmaceuticals announces FDA approval for Exparel manufacturing
Pacira Pharmaceuticals announced that the FDA approved an additional bulk manufacturing suite, referred to as Suite C, for Exparel. The suite is housed at the company’s Science Center Campus in San Diego, where Exparel is currently manufactured.
News For PCRX From The Last 14 Days
Check below for free stories on PCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
06:04 EDTPCRXPacira warning letter should not impact growth, says Jefferies
Jefferies believes the warning letter Pacira received over Exparel should not impact the drug's growth trajectory. The firm keeps a Buy rating on the stock with a $109 price target.
September 25, 2014
09:13 EDTPCRXOn The Fly: Pre-market Movers
HIGHER: LipoScience (LPDX), up 63% after agreeing to be acquired by LabCorp (LH) for $5.25 per share in cash... Magnum Hunter (MHR), up 12.5% after announcing that throughput volumes on Eureka Hunter's gas gathering pipeline system have increased to about 316,500 MMBtu per day... Jabil Circuit (JBL), up 4.7% following its report of better than expected fourth EPS and revenue... (JD), up 0.7% after the stock was initiated with an Outperform rating at Macquarie. LOWER: Yahoo (YHOO), down 0.6% after RBC Capital downgraded its rating on the stock to Sector Perform from Outperform, saying the risk/reward is less attractive following Alibaba's (BABA) initial public offering... HB Fuller (FUL), down 15% after reporting quarterly results and guidance that missed analyst estimates... Omnova Solutions (OMN), down 10.8% after its Q3 adjusted EPS missed expectations... Pacira Pharmaceuticals (PCRX), down 9.2% after receiving an FDA warning letter over certain promotional materials on Exparel.
06:32 EDTPCRXPacira Pharmaceuticals receives FDA warning letter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use